HC Wainwright Predicts Increased Earnings for Purple Biotech

Purple Biotech Ltd (NASDAQ:PPBT) – Analysts at HC Wainwright raised their FY2025 earnings estimates for shares of Purple Biotech in a report issued on Thursday, May 29th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($1.16) for the year, up from their previous estimate of ($1.65). The consensus estimate for Purple Biotech’s current full-year earnings is ($0.83) per share. HC Wainwright also issued estimates for Purple Biotech’s FY2026 earnings at ($0.62) EPS, FY2027 earnings at ($0.60) EPS and FY2028 earnings at ($0.58) EPS.

Purple Biotech Stock Performance

Shares of NASDAQ:PPBT opened at $2.68 on Monday. The firm has a 50 day simple moving average of $2.50 and a 200 day simple moving average of $3.13. Purple Biotech has a 52 week low of $2.00 and a 52 week high of $16.80. The company has a market cap of $3.57 million, a PE ratio of -0.30 and a beta of 0.57.

Purple Biotech (NASDAQ:PPBT) last announced its earnings results on Wednesday, May 21st. The company reported ($0.17) EPS for the quarter.

Institutional Trading of Purple Biotech

An institutional investor recently bought a new position in Purple Biotech stock. Two Sigma Securities LLC purchased a new position in Purple Biotech Ltd (NASDAQ:PPBT) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 15,374 shares of the company’s stock, valued at approximately $72,000. Two Sigma Securities LLC owned approximately 1.16% of Purple Biotech at the end of the most recent reporting period. 9.64% of the stock is currently owned by institutional investors and hedge funds.

Purple Biotech Company Profile

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage.